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Using an engineered high-affinity IFN-l, Mendoza et al. solve the structure of the IFN-l/IFN-lR1/IL-10Rb ternary signaling complex. The structure reveals how IL-10Rb can act as both a cross-reactive but cytokine-specific receptor. Structureactivity relationships of engineered type I and III IFNs provide insights into enhancing interferon functional potency.
INTRODUCTION
Lambda interferons (IFN-l1-4), also known as type III IFNs, are members of the IL-10 superfamily of cytokines (Kotenko et al., 2003; Sheppard et al., 2003) . Like type I IFNs, these secreted cytokines signal through cell surface receptors and elicit an innate immune response to combat viral infections and cancer (Donnelly and Steen and Gamero, 2010) . Recent studies highlight the importance and non-overlapping role of IFN-ls in curing persistent norovirus infections Nice et al., 2015) , and they also demonstrate efficacy against a number of other viral infections . While the type I IFN receptors are ubiquitously expressed, expression of the IFN-l receptor is restricted to immune cell subsets and barrier tissues. This feature gives IFN-ls unique potential for targeted therapies with fewer side effects then type I IFN therapies (Muir et al., 2014) . This promising antiviral activity of IFN-ls has led to their evaluation in clinical trials for use in hepatitis C virus (HCV)- (Muir et al., 2014) , hepatitis B virus (HBV)- Wang et al., 2015) , and hepatitis D virus (HDV)-infected patients (clinicaltrials.gov identifier NCT02765802).
Although type I IFNs and IFN-ls signal through entirely different receptors, they utilize the same Janus kinases, JAK1 and TYK2, and signal through a common JAK/STAT pathway to induce interferon-stimulated genes (ISGs), which elicit antiviral and immunoregulatory activities. Despite these similarities, the IFN-ls have lower potency in signaling (as measured by lower Emax of STAT activation), lower induction of interferon-stimulated genes, and higher EC 50 s for the antiviral and antiproliferative activities compared to type I IFNs (Ank et al., 2006; Dellgren et al., 2009; Dickensheets et al., 2013; Meager et al., 2005) . One explanation for their reduced potency is that IFN-ls form less stable ternary complexes than type I IFNs. In principle, a higher-affinity IFN-l could have improved clinical activity with less toxicity than type I IFNs.
The IFN-l receptor is composed of IL-10Rb and IFN-lR1, which forms sequentially in a two-step binding event. First, the IFN-lR1 subunit binds IFN-ls with high affinity, and it is the limited expression of this subunit that provides IFN-ls with their unique tissue specificity. In contrast, the IL-10Rb subunit is broadly expressed and binds the IFN-l binary complex with low affinity in the second step of complex formation. The IL-10Rb subunit is also shared by receptor complexes that engage the IL-10 superfamily members IL-10, IL-22, and IL-26 (Kotenko et al., 2003; Sheppard et al., 2003) . A crystal structure of unliganded IL-10Rb (Yoon et al., 2010) , together with binding studies of single point mutants, identified Tyr82 as playing a central role in its cross-reactive binding to IL-10 cytokines. Although models of ternary complexes of IL-10 family members have been proposed (Miknis et al., 2010; Yoon et al., 2010; Zdanov, 2010) , a complete structure is lacking, and it is still unclear how IL-10Rb recognizes a wide spectrum of ligands with their cytokine-specific receptors. Obtaining a ligand-bound structure to clarify this puzzle has been challenging, in part, because of the low affinity of IL-10Rb-ligand interactions (Logsdon et al., 2004; Yoon et al., 2006) .
Despite poor sequence conservation (< 25% identity), IL-10 superfamily cytokines are structurally conserved (Jones et al., 2008a; Zdanov, 2010) . The binary complex structures of IL-10 cytokines IL-22/IL-22R1, IL-10/IL-10R1, and IFN-l1/IFN-lR1 (Bleicher et al., 2008; Jones et al., 2008b; Josephson et al., 2001; Miknis et al., 2010; Zdanov, 2010 ) adopt a similar ligand-receptor docking topology governed by contacts near the inter-domain ''elbow'' of their high-affinity receptor chains. Mutagenesis studies combined with computational docking models have lead to several proposed models of IL-10 superfamily ternary complexes, yet an experimentally determined structure has been elusive (Bleicher et al., 2008; Gad et al., 2009; Jones et al., 2008a; Logsdon et al., 2004; Miknis et al., 2010; Wu et al., 2008; Yoon et al., 2006 Yoon et al., , 2010 Zdanov, 2010) .
We decided to take an affinity maturation approach to increase the binding affinity of IFN-l3 for the IL-10Rb subunit, so as to facilitate crystallization of a ternary complex. This approach enabled the isolation of a higher affinity IFN-l3 variant, and the purification of a stable IFN-l/IL-10Rb/IFN-lR1 ternary complex. Structural analyses of the ternary complex revealed a network of tyrosine residues that serve as hydrophobic anchor points to engage IL-10 family cytokines. In addition, the high-affinity variant had increased antiviral and antiproliferative properties. In contrast, engineering of type I IFNs did not significantly increase downstream signaling or antiviral activity, suggesting that these are already at a maximum. Taken together with the lower toxicity profiles of IFN-ls, our findings argue for the further development of type III IFNs as alternative antiviral and anticancer therapeutics.
RESULTS

Engineering a High-Affinity Type III Interferon
We used yeast surface display as a platform to engineer a higher-affinity IFN-l for structural and functional studies. We focused our efforts on IFN-l3 because a crystal structure has been reported and because it has the highest antiviral potency among the natural IFN-ls . We targeted the interaction between IFN-l3 and IL10Rb for affinity maturation because it is of much lower affinity than the interaction between IFN-l3 and IFN-lR1. When displayed on yeast, IFN-l3 bound to IFN-lR1 with a titration midpoint of approximately 400 nM (Figures S1A and S1B). We were unable to detect binding of IFN-l3 to either a monomeric (data not shown), or an avidity-enhanced tetrameric form of IL-10Rb ( Figure 1A , left panel). However, in the presence of IFN-lR1 tetramers, IFN-l3 bound to tetrameric ( Figure 1A , right panel), but not monomeric IL-10Rb ( Figure 1A , middle panel). Thus, yeast displayed IFN-l3 is properly folded and forms a binary complex with IFN-lR1 that is recognized by IL-10Rb, albeit with very low affinity ( Figure 1A) . We carried out IFN-l3 affinity maturation experiments for IL-10Rb in the presence of soluble IFN-lR1.
To increase the affinity of the IFN-l3/IL-10Rb interaction, yeast-displayed IFN-l3 was mutagenized using error-prone PCR in a first-generation library and gene shuffling in a second-generation library, and higher-affinity mutants were selected with fluorescently labeled streptavidin-bound IL-10Rb. The firstgeneration yeast library contained 1 3 10 8 clones expressing IFN-l3 and was subjected to four rounds of increasingly stringent selections ranging from 400 nM IL-10Rb tetramers in the first round to 1 mM IL-10Rb monomers in the fourth round. The enriched library showed some binding to 1 mM IL-10Rb monomers ( Figure 1B , top two histograms). 96 clones were screened for 1 mM IL-10Rb monomer binding and the affinities of interacting clones were measured by titrations with the IL-10Rb receptor. The six highest affinity clones, (all of which had > 1 mM affinity for IL-10Rb), were then used as parental templates in a DNA shuffling reaction ( Figure 1C ). The resulting second generation library contained 1x10 8 clones and was subjected to three rounds of selection against decreasing concentrations of IL-10Rb monomer ranging from 1 mM to 125 nM ( Figure 1B , bottom two histograms). 96 clones were screened for binding to IL-10Rb followed by yeast-surface titrations to measure affinity. The highest affinity clone, denoted ''H11,'' was found to have an ''on-yeast'' KD of 200 nM to IL-10Rb ( Figure 1C ). Sequence analysis of H11 revealed that the gene contained five mutations relative to wild-type IFN-l3 and was a combination of four first generation sequences from the DNA shuffling reaction ( Figures 1C and  S1C ). H11 was expressed recombinantly and the affinity of IL-10Rb to the immobilized H11/IFN-lR1 binary complex was determined by surface plasmon resonance. The H11/IFN-lR1 complex showed a 30-fold increase in IL-10Rb affinity (KD = 560 nM) compared to the wild-type IFN-l3/IFN-lR1 binary complex ( Figure 1D ). H11 has a 5-fold higher affinity for IFN-lR1 (KD$150 nM) relative to the wild-type IFN-l3 affinity for IFNlR1 (KD$850 nM) ( Figure S1D ). One of the H11 mutations, Thr150Ala, is located at the center of the IFN-lR1 binding site. Collectively, the mutations in H11 increased its affinity for both IFN-lR1 and IL-10Rb by 150-fold.
Structure of the IFN-l3 Receptor Ternary Complex
The lack of a complete structure of a ternary complex of an IL-10 family cytokine is likely due to the low affinity of IL-10Rb. Indeed, when we attempted to form a ternary complex between wildtype IFN-l3, IFN-lR1, and IL-10Rb, we did not observe a stable ternary complex by gel filtration chromatography. However, IFN-l3 H11 was able to form a stable ternary complex with IFN-lR1 and IL-10Rb ( Figure S1E ). We crystallized the N-glycan minimized ternary complex using IFN-lR1 expressed from HEK293 GnTi À cells (which was treated with Endoglycosidase F and H), and a mutant form of IL-10Rb (expressed from insect cells) in which four N-linked glycan sites were mutated to Gln. This complex yielded crystals that diffracted X-rays to 2.85 Å (Table S1). The structure of the ternary complex was solved using molecular replacement with the binary structure of IFN-l1/IFNlR1, PDB: 3OG6 (Miknis et al., 2010) and the unbound structure of IL-10Rb, PDB: 3LQM (Yoon et al., 2010) . No changes in domain orientations were observed from either the IFN-l1/IFNlR1 binary (RMSD 0.7 Å ) complex, the apo IL-10Rb (RMSD 1.3 Å ), or IFN-l3 structures (RMSD 0.6 Å ) (PDB: 3HHC) (Figures S3A-S3C ). IL-10Rb makes extensive and contiguous contacts with the H11/IFN-lR1 binary complex, interacting with H11 through sites 2a and 2b and with the IFNlR1 stem at site 3 ( Figure 2A , left panel). The overall binding topology of the IFN-l3/IFN-lR1/IL10Rb ternary complex exhibits both similar and distinct features compared to previously determined cytokine receptor complexes (Spangler et al., 2015) . The shared IL-10Rb receptor binds H11 at the far end of the helical bundle rather than more centrally on the face of the helical bundle, as is typical of other cytokine/ receptor binding topologies (Spangler et al., 2015) (Figure 2A , middle and right panels). While the type I IFNs (PDB: 3SE4) (Thomas et al., 2011) and IFN-ls share common signaling pathways and immune activities, the ternary structure of the IFN-l receptor complex exhibits a distinct overall geometry ( Figure 2C ). The two type I IFN receptors bind on opposing faces of the helical bundle of the cytokine, contrasting to the IFN-l ternary complex. A further distinguishing feature of IFN-l ternary complex is the role of receptor stem-stem contacts, which has not been seen in the type I IFN complexes. Another interesting comparison is with the structure of the IL-10/IL-10R1 binary complex (PDB: 1J7V) (Josephson et al., 2001) (Figure 2B ), which is not a complete signaling complex because it lacks IL-10Rb in the structure. IL-10 is the founding member of the IL-10 superfamily and is a non-covalent dimer (Tan et al., 1993) , with each IL-10Rb bound to IL-10 to create a 2:2 stoichiometry, distinct from that of the 1:1:1 IFN-l3 H11/IFN-lR1/IL-10Rb ternary complex. It remains unclear where IL-10Rb binds to IL-10 and how this can be geometrically accommodated in the higher order IL-10 family complexes. However, the binding geometry of IL10Rb to IFN-l3 and IFN-lR1 could yield clues to IL-10Rb binding modes in the other IL-10 family complexes.
In the complex structure, three IL-10Rb loops, 2, 3, and 5, contain aromatic residues that undergo large conformational changes (2.4 -6.5 Å ) relative to the apo IL-10Rb structure (PDB: 3LQM) (Yoon et al., 2010) . Notably, residues in loop 5 of IL-10Rb are situated to share hydrogen bonds with both cytokine and co-receptor residues at sites 2b and 3 ( Figure 2A ). Tyr59 in loop 2 of IL-10Rb binds IFN-l3 H11 in a pocket formed by helices (A) The structure of the ternary complex reveals the mechanism of IL-10Rb (gold) recognition of IFN-l3 H11 (blue) and IFN-lR1 (gray). The IL-10Rb makes extensive and continuous contacts with H11 at sites 2a and 2b, and site 3 makes stem-stem contacts with the IFN-lR1. Unique to the IFN-l structure, a large surface area of the cytokine remains surface exposed in the ternary complex. (B) Structure of the IL-10/IL-10R1 partial signaling complex (PDB: 1J7V) (Josephson et al., 2001 ). (C) Structure of a type I IFN receptor complex (PDB: 3SE4) (Thomas et al., 2011) . See also Table S1 .
C and D of the cytokine ( Figures 3A-3B , and S2). Notably, the H11-specific mutation Glu73Asp (Helix C) forms a hydrogen bond with the hydroxyl group of Tyr59, stabilizing the interaction between the H11/IFN-lR1 binary complex and IL-10Rb ( Figures  3B, S2D ). Tyr82 on loop 3 of IL-10Rb, also binds to IFN-l3 H11 at site 2a and sits in the pocket formed between the N terminus and helices A and D of the cytokine ( Figures 3A-3B, S2E ). In this position, Tyr82 shares two hydrogen bonds with the cytokine: one between the backbone carbonyl of Tyr82 and Nε of His91 (H11) and a second between the hydroxyl group of Tyr82 and the nitrogen backbone of Ser13 (H11) ( Figures 3B, S2E) .
At site 2b, Tyr140 and Trp143 of loop 5 (IL-10Rb) bind IFN-l3 H11 by ''pinching'' the N terminus of Helix A ( Figures 3A and 3B ). In the ternary complex structure, Tyr140 (IL-10Rb) forms two hydrogen bonds with H11 residues Gln18 and Gln15Arg, the latter of which is an engineered mutation of S2F) . Trp143 packs against the hydrophobic backbone of Helix A and contributes van der Waals interactions as well as a hydrogen bond shared with the backbone carbonyl of the N-terminal residue Ser11 (H11) ( Figure 3B ). Single alanine substitutions at sites 2a and 2b interface positions-Gln15, Gln88, or His91 in the wild-type background-result in a decrease in binding efficiency to IL-10Rb ( Figures S3D-S3F ). These residues account for 9%, 5%, and 14% of the total buried surface area shared with IL-10Rb and are important for binding, consistent with the observation that Gln88Ala IFN-l3 was reported to have a 50-fold increase in the EC 50 for the AV activity relative to the wild-type .
Given that IL-10Rb is shared among several different cytokines, we compared the interface chemistry of IL-10Rb cytokine recognition to that of two other shared cytokine receptors, gc and gp130 (Boulanger et al., 2003a; Wang et al., 2005 Wang et al., , 2009 Yoon et al., 2010) . All three shared receptors place aromatic residues in the central contact positions with the cytokines. When the cytokine-binding homology regions (CHR) are aligned, we find that Tyr82 of IL-10Rb is analogous to Tyr103 of gc (PDB: 2B5I) (Wang et al., 2005) and Phe169 of gp130 (PDB: 1P9M) (Boulanger et al., 2003a) , which dock onto hydrophobic pockets on their respective cytokines ( Figure 3C ). Each of the cytokines (IFN-l, IL-2, and IL-6) varies in shape and size of the surface area. The total buried surface area of the IFN-l3/IL-10Rb interface is large (1640 Å 2 ) with deep hydrophobic pockets on the face of IFN-l which contrasts to the relatively flat and smaller interfaces of IL-6 (1272 Å 2 ) (Boulanger et al., 2003a) and IL-2 (970 Å 2 ) (Wang et al., 2005) (Figures 3D-3F ). Another differentiating feature is that Tyr82 of IL-10Rb shares two hydrogen bonds with IFN-l that stabilize the ligand-receptor interaction, which is not observed with Tyr163 of gc or Phe169 of gp130. The centrality of aromatic residues that are capable of extensive chemical and structural plasticity in forming interface contacts with diverse cytokines appears to be a theme exploited by shared receptors to facilitate cross-reactivity (Boulanger et al., 2003b) .
Site 3 represents the interface between the receptor stem domains D2 of IFN-lR1 and SD2 of IL-10Rb. The site 3 interface extends from site 2b to the C-termini of the membrane-proximal receptor domains (Figure 2A ). The total buried surface area is large (1417 Å 2 ) and is composed of mainly van der Waals interactions with four hydrogen bonds interspersed. In comparison to the shared gp130 and gc shared receptor systems, the analogous gp130/IL-6Ra interface has a smaller total buried surface area (1074 Å 2 ) (Boulanger et al., 2003a) while gc/IL-2Rb (1750 Å 2 )
has the larger stem-stem interface, containing 17 hydrogen bonds shared between the two co-receptors (Wang et al., 2005) . At the IFN-lR1 and IL-10Rb interface, hydrogen bonds are observed between the side chain of Arg130 (IL-10Rb) and the backbone carbonyl Gln163 (IFN-lR1), and side chain to side chain hydrogen bonds are observed between His128 (IL-10Rb) and Gln163 (IFN-lR1), Glu141 (IL-10Rb) and Tyr189 (IFN-lR1), and Thr142 (IL-10Rb) and Thr183 (IFN-lR1) ( Figures  S2B and S2C ). As the collective binding and structural studies indicate, the site 3 receptor stem-stem contacts play an important role in the recruitment of IL-10Rb to the IFN-l3 H11/IFNlR1 binary complex.
Implications for a Shared IL-10Rb Binding Mode to IL-10 Family of Cytokines
Using the IFN-l ternary complex as a structural template, we structurally aligned the IFN-l ternary complex onto the binary structures of IL-22/IL-22R1 (PDB: 3DLQ) (Bleicher et al., 2008) and IL-10/IL-10R1 (PDB: 1J7V) (Josephson et al., 2001 ) in order to elucidate the molecular basis of IL-10Rb binding and recognition ( Figure 4A , left and middle). The structure of the IFN-l3 H11/ IFN-lR1/IL-10Rb ternary complex revealed that IL-10Rb makes contacts with three cytokine helices: A, C, and D. Mutations associated with impaired binding of multiple IL-10 family members to the shared IL-10Rb Logsdon et al., 2004; Wu et al., 2008; Yoon et al., 2010) fell within the IFN-l3 H11 binding region of the receptor and contact hotspot tyrosine residues of IL-10Rb ( Figure 4A , right, red surface). Structurebased sequence alignment of the three cytokines indicated that residues mapping to the IL-10Rb binding site are highly divergent ( Figures 4B, S3G ). Despite a lack of sequence conservation, structural comparison of the IFN-l3, IL-10, and IL-22 residues within the site 2 interface revealed that the three cytokines have a conserved pattern of hydrophobic patches at the sites of the IL-10Rb tyrosine docking ( Figure 4C ), which are surrounded by polar residues. Thus, IL-10 family members appear to have evolved chemical complementarity with IL-10Rb through distinct pairwise interactions. Figure 5A ), consistent with previous studies (Dickensheets et al., 2013; Kotenko et al., 2003) in which type I IFN signaling is stronger in unmodified cells. Similarly, H11 induced ISGs more potently than wild-type IFN-l3 in Hap1 cells, although gene induction remained well below levels induced by IFN-u ( Figures 5B and S4A ). H11 improved antiviral activity in Huh7.5 cells infected with HCV, with potency 12-fold higher than wild-type IFN-l3, though 10-fold less potent than IFN-u ( Figure 5C ). Both wild-type IFN-l3 and H11 elicited minimal antiproliferative activity ( Figure 5D ), which has been previously observed in vitro (Lasfar et al., 2006) . We hypothesized that the lack of antiproliferative activity could be due to the limited expression of IFN-lR1 on Huh7.5 cells (Moraga et al., 2009; Zhou et al., 2007) . Indeed, when IFN-lR1 was transduced into Huh7.5 or WISH cells, an IFN-l non-responsive cell line, the IFN-ls robustly induced an antiproliferative response ( Figure 5E ). As anticipated, the effect of the high-affinity H11 was stronger than that of the wild-type IFN-l3 and the magnitude of this difference depended on relative levels of IFN-lR1 expression ( Figure S4B ). Taken together, these experiments suggest IFN-l antiproliferative activity might be limited by both IFN-lR1 receptor expression and stability of the IFN-l signaling complex; the latter can be addressed through affinity maturation (Figures 5D and5E, and S4) .
To test whether the improved in vitro AV potency of H11 over wild-type IFN-l3 results in enhanced in vivo antiviral efficacy, we tested our engineered interferon in a mouse model of HBV infection. We made use of the fumarylacetoacetate hydrolase deficient (Fah À/À ) liver chimeric model developed by Grompe and colleagues, in which liver injury is controlled by administration of 2-(2-nitro-4-trifluoro-methyl-benzoyl)-1, 3 cyclohexanedione (NTBC) (Grompe et al., 1995) . After transplantation of human fetal hepatoblasts into immunodeficient FRG mice (Fah
) (Billerbeck et al., 2016) , we induced mouse liver damage by intermittent withdrawal of the protective drug NTBC and monitored engraftment levels over time by measuring human albumin (hAlb) levels in the sera ( Figure 5F ) (Bissig et al., 2010; de Jong et al., 2014) . Mice were challenged with HBV upon peaking hAlb levels. Once HBV viremia had reached its plateau, the infected mice were subjected to IFN-l3-based antiviral treatment. IFN-l3 H11 suppressed HBV viral load more effectively than the IFN-l3 wildtype regimen ( Figure 5G ). Similarly, although the difference was minor, HBV surface antigen (sAg) levels were lower for the H11 relative to the wild-type treated mice over the course of treatment (p = 0.0083) ( Figure S4C ). Human albumin levels, which serve as a proxy for toxicity, remained stable during the course of treatment, excluding the possibility of human hepatocyte loss and suggesting the higher-affinity IFN-l was no more toxic than the wild-type. (Figure S4D ). Thus, although modest, H11 demonstrates improved therapeutic efficacy without obvious toxicity. These combined data suggest that further affinity improvements, now using the crystal structure of the ternary complex as a guide, might yield a therapeutically improved IFN-l for both antiviral and anti-cancer therapy.
Probing the Plasticity of Type I Interferon Function through Structure-Guided Protein Engineering
Our engineering efforts improved the antiviral and antiproliferative potency of IFN-l3 but its potency still lagged behind type I IFNs. Thus, we aimed to characterize the plasticity and potency of the type I IFNs through engineering. This information could potentially be informative for understanding the basis of the potency differences between the two IFN families, but also to establish a benchmark of activity for future IFN-l engineering efforts. In the type I IFN system, several prior studies using gene shuffling show that affinity improvement also manifests as improved antiviral potency (Brideau-Andersen et al., 2007; Chang et al., 1999) . However, a more comprehensive series of type I IFN engineering studies conclude that wild-type IFNs are already at an AV potency maximum, and there is little to gain from affinity maturation (Jaitin et al., 2006) . To resolve this discrepancy, we probed the sensitivity of type I IFN antiviral and antiproliferative functions to receptor affinity using a HTP combinatorial engineering approach.
We were guided by the structure of the type I interferon, IFN-u, in complex with the IFN-aR1 and IFN-aR2 receptors ( Figure 6A ). We generated a site-directed mutagenic library of IFN-u that diversified its IFN-aR1 binding interface, the lower-affinity site, as a means of creating variants with modified antiviral and antiproliferative activities ( Figure 6A) . We enriched the library for binders to wild-type IFN-aR1 affinity (KD = 1 mM). In order to find the most interesting variants with diverse activities, we developed a high-throughput functional screen, and characterized 288 randomly selected clones from the library ( Figure 6B ). For our screen, distinct type I IFN variant proteins were cleaved from yeast cells, and the released cytokines in the supernatant were purified by filtration. The IFN-containing supernatant was then used to treat cells ( Figure 6B ). Based on their diverse antiproliferative and antiviral activities, we selected four IFN-u variants for recombinant expression and characterization. Previously, we rationally designed an IFN-u variant (Lys152Arg), with 100-fold higher affinity for the IFN-aR2 receptor than the wild-type cytokine (Thomas et al., 2011) . We thus added the Lys152Arg mutation to each of the four variants from the HTP screen. In addition to these mutants, we biophysically and biochemically characterized the wild-type IFN-u, , and a shuffled IFN-a mutant (Maxygen 9x25) that was previously reported to be biased toward antiviral activity (Brideau-Andersen et al., 2007) .
We measured signaling potency (phospho-STAT1), gene induction, and antiviral and antiproliferative activities of our panel of engineered interferons relative to wild-type IFN-u ( Figure 6C ). We also determined the affinity of each cytokine for the IFN-aR1 and IFN-aR2 subunits via surface plasmon resonance (Table S2) . Receptor affinity was not used as a criterion for selection of the variants, rather, variants were chosen based on differential antiviral and antiproliferative activity, we aimed to interrogate the correlation between complex stability (Kalie et al., 2008; Lavoie et al., 2011; Piehler et al., 2012; Thomas et al., 2011) (the product of the cytokine KDs for binding each receptor subunit) and cytokine activity. Affinities for IFN-aR1 ranged from 20 nM to 300 mM (wild-type IFN-u KD = 1.2 mM). Affinities for IFN-aR2 were between 2 nM for the unmodified IFN-u and 200 pM in the Lys152Arg background. In all, our IFN variant complexes sampled a 5.7-log range of complex stabilities (Table S2 ). The EC 50 s of our variants for STAT signaling and antiviral activity were found to be insensitive to changes in affinity, as illustrated by both minimal improvement over the wild-type EC 50 s and narrow range of EC 50 s (0.85 and 1.2 logs, respectively) for the broad range of complex stabilities ( Figure 6C , left and middle panels, Table S2 ). In contrast, antiproliferative activity varied by 3.5 logs and correlated (R = 0.67) with complex stability (Figure 6C, right) . We measured induction of a representative set of ISGs by seven of our IFN variants on Huh7.5 cells (Figure 6D ). As observed with the differential effects of complex stability on antiviral and antiproliferative activities, high-affinity variants offered little improvements in gene induction (such as ISG15 and MX1) over the wild-type ( Figure 6D , two left panels) while other genes (like APOL3 and SAM9DL) were more sensitive to complex stability ( Figure 6D , two right panels) (Levin et al., (A) A site-directed IFN-u library designed to mutagenize the low affinity IFN-aR1 site was combined with a rationally designed affinity-enhancing Lys152Arg mutation at the IFN-aR2 interface on the cytokine. The SD4 domain of IFN-aR1 was modeled to the complex (PDB: 3SE4) (Thomas et al., 2011) using the mouse IFN-aR1 structure (PDB: 3WCY). (B) 288 clones were screened for activity using a high-throughput functional screen. Displayed IFNs were cleaved from yeast by the site-specific 3C protease. The filtered supernatants were then used to treat VPN53 (Moraga et al., 2009) Table S2. 2014). This observation is in accord with several previous studies (Jaitin et al., 2006; Kalie et al., 2008; Lavoie et al., 2011; Thomas et al., 2011) . Given the apparent lack of off target toxicities of IFN-ls compared to type I IFNs (Muir et al., 2014; Sato et al., 2006) , these data provide conceptual support for engineering an IFN-l to match the AV potency of type I IFNs, but it remains to be determined whether the diminished side effects of IFN-l will persist in forms with potency equal to that of type I IFNs.
DISCUSSION
In this study, we implemented a protein engineering strategy to gain structural access to the IFN-l/IFN-lR1/IL-10Rb ternary complex, and to assess the relative potential for enhancing the functional efficacies of type III and type I IFNs. The ternary complex illuminated several important molecular features governing the IL-10Rb interactions with IL-10 family cytokines, which are of extremely low affinity. Previously, the divergent sequences within the IL-10 superfamily cytokines placed substantial limitations on our ability to engineer IL-10 cytokine variants with enhanced signaling and functional activities. With the structure in hand, we observed how IL-10 superfamily cytokines present three hydrophobic patches on their surface that interlock with aromatic residues on inter-domain loops of IL-10Rb. Additionally, the structure revealed the importance of extensive IFNlR1/IL-10Rb stem-stem interactions in stabilizing the ternary complex, clearly showing that a composite interface presented by each of the IL-10 family cytokines with their respective high-affinity receptors is required for IL-10Rb recognition.
IFN-l3 exhibits 60-fold more potency, as measured by antiviral EC 50 s, than IFN-l2, suggesting that type III IFN antiviral activity could be enhanced. We anticipated that this effect could be further exaggerated through molecular engineering approaches given that type III IFNs bind IL-10Rb with nearly undetectable affinities in vitro. Using directed evolution, we identified variants with up to 150-fold increased complex stability, which resulted in a 100-fold improvement in the EC 50 for pSTAT1 signaling and 12-fold improvement in the EC 50 for antiviral activity. Studies of HBV-infected human-liver chimeric mice validated this improved potency in an in vivo setting by demonstrating that an engineered IFN-l can improve upon the efficacy of the wild-type cytokine; a quality recent clinical trials have indicated as being clinically desirable (Chan et al., 2016) . A more potent IFN-l which maintains a low toxicity profile compared to type I IFNs, would provide new avenues for treatment of chronic infections such as HBV, HCV, and HBV co-infections with HDV, and might be useful as a broad spectrum antiviral (Ciancio and Rizzetto, 2014) .
In vitro, IFN-ls have a blunted antiproliferative activity (Lasfar et al., 2006) , which effects could be rescued by overexpression of the IFN-lR1 receptor. Indeed, the engineered IFN-l was more potent than the wild-type. While the minimal antiproliferative effects on untransduced cell lines might appear to suggest that IFN-ls have limited potential as anti-cancer agents, in vivo studies paint a different picture. IFN-ls can significantly inhibit tumor growth in murine cancer models (Lasfar et al., 2006; Numasaki et al., 2007; Sato et al., 2006) with less toxicity than type I IFN treatment (Sato et al., 2006) . This gives hope for continued cancer-related efforts.
We also developed a panel of type I IFN proteins with a range of affinities to probe the molecular mechanism underlying the observed differences in antiviral and antiproliferative potencies of type I versus type III IFNs. In vitro antiviral studies have established the type III IFNs to be less potent than the type I IFNs, which translates into a lower efficacy in the clinic, as observed in recent HCV (Muir et al., 2014) and HBV Wang et al., 2015) clinical trials. Previous studies of the type I IFNs have demonstrated a modest 2-fold difference in antiviral potency between the highest affinity natural IFN (IFN-b) or engineered IFN such as IFN-a2 YNS (Kalie et al., 2007) relative to lower affinity ligands such as IFN-a2. However, one study reported engineering type I IFNs with >20-fold improved antiviral activities but relatively unchanged antiproliferative activities (Brideau-Andersen et al., 2007) . This study measured antiproliferative activity using the Daudi cell line, which is more sensitive to antiproliferative effects, possibly leading to aberrant antiproliferative:antiviral ratios. Here, using structure-based engineering of type I IFNs, we demonstrate that STAT signaling potency and antiviral activity were insensitive to complex stability and stable relative to wild-type levels (Kalie et al., 2007 (Kalie et al., , 2008 Lavoie et al., 2011; Thomas et al., 2011) . By contrast, antiproliferative activity was directly correlated with complex stability (Levin et al., 2014) . This observation held true for the synthetic IFN, 9x25, which was previously reported to have a 20-fold improvement in antiviral activity over a wild-type IFN (Brideau-Andersen et al., 2007) . In this study, the antiviral activity of the shuffled IFN (EC 50 = 140 pM) was similar to IFN-u (EC 50 = 100 pM) and had a 48-fold improvement in the antiproliferative activity over wild-type IFN-u, consistent with a 3-log improvement in complex stability. Collectively, these experiments demonstrate that type I IFNs vary in their antiproliferative:antiviral profiles mainly due to differences in antiproliferative potencies between ligands as a result of varied receptor affinities.
Although we were able to engineer a type III IFN with improved signaling and antiviral activities, our IFN-l3 H11 variant remained less potent than type I IFNs. The type III IFN ternary complex will guide efforts to engineer even more potent cytokines, which can potentially close the gap in efficacy between the type I IFNs and type III IFNs. Moreover, the true respective clinical potential of these different interferons will also need to take into account their respective side effects. Because the latter are highly dependent on the receptor distributions, engineered IFN-l3 variants such as H11 might have unique advantages in the clinic.
EXPERIMENTAL PROCEDURES
Yeast Surface Display of IFN-u and IFN-l3 For both type I and III IFNs, the cytokines were displayed on yeast as previously described (Levin et al., 2012) but containing a 3C rhinovirus protease tag at the N terminus. Staining and selection was performed via streptavidin-phycoerythrin labeled receptors with separation of the receptoryeast population by paramagnetic anti-phycoerythrin microbeads (Miltenyi; MACS). Expression on the yeast surface was assayed by staining with the Myc-tag antibody conjugated to Alexa 647 (Cell Signaling). Progression of the enrichment was monitored by the receptor yeast staining by flow cytometry (BD Accuri). A site-directed library was used for engineering type I IFNs. A round of error-prone PCR and DNA shuffling (Brideau-Andersen et al., 2007) was used for the second-generation of IFN-l3 variants. Single-point variants of IFN-l3 were generated by Quick-Change Mutagenesis, transformed, and displayed on yeast.
Functional Screen for IFN-u
Individual clones from the library were plated on SD-CAA plates, grown in a 96-deep well format. The protein for each clone was cleaved from the yeast using rhinovirus 3C protease, separated from the yeast by filtration (Whatman Unifilter 800), and assayed for antiviral activity by tracking HCV replication in Gaussia luciferase-based reporter Huh7.5 cells and antiproliferative activity in PVN53 (Moraga et al., 2009 ) cells by measuring cell density as previously described (Thomas et al., 2011) . Variants with diverse activities were selected for recombinant expression and characterization.
Protein Expression, Purification, and Structural Determination Type I IFN cytokines, type I IFN receptors, type III IFNs, and type III receptors were expressed in the Hi5 insect expression system, purified as previously described (Thomas et al., 2011) and stored in 10% glycerol. For crystallography, all four glycosylation sites in IL-10Rb were mutated from Asn to Gln as described in Yoon et al. (2010) . IFN-lR1 was expressed in HEK293 GnTi À cells and de-glycosylated by treatment with EndoF and EndoH. The methylated ) IFN-l3 H11/IFN-lR1/IL-10Rb complex was purified by size exclusion chromatography on a S75 column (GE). Crystals were obtained within 24 hr at 20
C from the MCSG3 screen (Anatrace) and optimized to 0.2 M Ca acetate, 0.1 M imidazole pH 8.0, 10% PEG8000, and 3% sucrose as an additive (Catalog #HR2-138, Hampton). Cryoprotectant was the mother liquor plus 8% each of sucrose, glucose, and xylitol. Crystallographic data were collected at the Advanced Light Source (ALS) Beamline 8.2.1. Data were indexed, integrated, and scaled using XDS or HKL2000 program suites. Crystal structures were solved by molecular replacement with the program PHASER using the IFN-l1/IFN-lR1 binary complex (PDB: 3OG6) (Miknis et al., 2010) and apo IL-10Rb (PDB: 3LQM) (Yoon et al., 2010) structures as search models. The final structure was built by iterative cycles of reciprocal space refinement with PHENIX and BUSTER and manual rebuilding with COOT. Crystallographic software used in this project was installed and configured by SBGrid.
Sequence, Structural, and FACS Analysis Promals3D was used to perform a structure based sequence alignment (Pei et al., 2008) . Sequence alignments and percent identity calculations were performed with JalView (The University of Dundee). Structural alignments, homology models, and distance calculations, and figures were generated in Pymol (Schrö dinger, LLC). Buried surface area was calculated using PISA (Krissinel and Henrick, 2007) . Figures of FACS data were generated with either R with the Bioconductor source (R-project) or Prism (GraphPad Software).
Surface Plasmon Resonance GE Biacore T100 was used to measure the KD by either kinetic (type I IFNs) or equilibrium (type III IFNs) methods. Approximately 100 RU of each of the receptors were captured on a Biotin CAP-chip (GE) including a reference channel of an unrelated cytokine receptor (IL-2Rb).
In Vitro Characterization
For type I IFNs, signaling, antiviral and antiproliferative assays were performed as previously described (Thomas et al., 2011) . For measuring gene induction, Huh7.5 cells were plated in a 6-well format and treated with 1 nM type I IFNs for 24 hr, Hap1 cells (a gift from Jan Carette) were treated with 5 pM type I or III IFNs for 6 hr, RNA was extracted with the RNeasy Micro kit (QIAGEN), which was converted to cDNA by a RT-PCR reaction (HC RNA-to-cDNA kit, Thermo Fisher Scientific), and ISG induction relative to the untreated controls and normalized to 18S levels were measured by the Taqman qPCR assay system on a StepOnePlus instrument (Thermo Fisher Scientific) following manufacture instructions. For type III IFNs, pSTAT1 signaling was performed as previously described (Thomas et al., 2011) except Hap1 cells were detached after IFN treatment by incubating with trypsin (GIBCO) for 5 min before fixing and staining.
Antiproliferative Activity of Type III IFNs Lentiviral pseudoparticles were generated by co-transfecting 4 3 10 5 Lenti-X 293T cells (Clontech) in poly-L-lysine coated 6-well plates with plasmids expressing the pLX304 proviral DNA encoding human IFN-lR1, HIV-1 gag-pol, and VSV-G at a ratio of 1.1/0.7/0.2, respectively. For each transfection, 5 ml Lipofectamine 2000 (Thermo Fisher Scientific) was combined with 2.0 mg total DNA in 100 ml Opti-MEM (GIBCO). Transfections were carried out for 6 hr, followed by a medium change to DMEM containing 3% FBS. Supernatants were collected at 24 hr and 48 hr, pooled, passed through a 0.45 mm filter and stored at À80 C. 3 3 10 5 Huh7.5 and WISH cells were resuspended in DMEM containing 10% FBS, 500 mL lentivirus, and 8 mg/ml polybrene in a total volume of 1.5 mL and spinocualted in 12-well plates for 1.5 hr at 850 3 g. 48 hr post transduction the cells were selected with 2.5 mg/ml blasticidin. Huh7.5 and WISH cells were harvested in PBS + 5 mM EDTA and washed twice with cold PBS + 0.5% BSA. Cells were then incubated with anti-IL-28RA (R&D Systems; cat# AF5260) at 5 mg antibody per 1 3 10 6 cells in 0.4 mL volume for 30 min, washed 3 times, incubated with FITC conjugated anti-sheep IgG (Abcam; cat# ab6743) at 1:2000 dilution for 30 min, and washed 3 times prior to cell sorting into low, medium, and high IFN-lR1-expressing populations using a BD FACSAria flow cytometer. HepG2, Huh7.5 and WISH cells were seeded at 1 3 10 3 cells/well in 96-well plates. The following day media was replaced with 100 ml/well of IFN-containing media. 4 days post IFN treatment cell density was measured using CellTiter-Glo (Promega) according to the manufacturer's protocol.
Generation of HBV-Infected Human-Liver Chimeric Mice and IFN-l3 Therapy Human hepatoblasts were isolated from human fetal livers procured from Advanced Bioscience Resources (ABR), as described (Andrus et al., 2011) ., and injected intrasplenically (1 3 10 6 cells per mouse) into male Fah
Il2rg null (FRG) mice originally obtained from Marcus Grompe (Grompe et al., 1995) . Starting on the day of transplantation, mice were cycled off the liver protective drug NTBC (Yecuris) as described by others (Azuma et al., 2007; Bissig et al., 2010) . Human albumin levels in mouse sera were measured by ELISA (Bethyl Laboratories). Human liver chimeric mice were injected intravenously with 100 mL of mouse serum containing 2 3 10 8 DNA copies/ml of HBV that originated from a genotype C eAg negative patient. For HBV viral load measurements, DNA from 25 mL of mouse serum was isolated using a DNA extraction kit (QIAamp DNA Blood Mini, QIAGEN) and copy number was analyzed by an in-house Taqman assay as described previously (Shlomai et al., 2014) . HBsAg (Autobio Diagnostics) levels in mouse serum were determined by CLIA per manufacturers' instructions. Eight mice were randomized for daily treatment for four weeks with intraperitoneal injections of vehicle (15% glycerol in PBS), wild-type IFN-l3 or H11 at 10 mg/kg body weight (2, 3, and 3 mice respectively). Every time point, data were plotted normalized to baseline values and relative to controls. Statistical analysis was performed using the regular two-way ANOVA with Bonferroni multiple comparison posttest in GraphPad Prism. 
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